BeStock  
Stocks › Biotechnology › BMRN

Biomarin Pharmaceutical BMRN

US equityMarket cap rank #1288Biotechnology
$60.41 −$1.01 (-1.64%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $60.02 -0.65%
Open$61.53
Prev close$61.42
Day range$59.84 – $62.01
Volume6.06M
Market cap$11.70B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership104.2%+1.32 pts vs. prior quarter
Institutions holding697+6 vs. prior quarter
Insider trades (recent)30 buys / 20 sellsNet buying
Short interest7.30% of floatDays to cover 5.8 · as of 30 Oct 2026
Short-sale volume share19.3%5-day average of daily volume

Short-sale volume as % of daily volume

14%21%29%36%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$24.02M (16 inflow days, 4 outflow days).

Net flow by order size, last 20 sessions

+$17.2MSuper+$6.8MBig+$16.3MMid+$4.8MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 33.7% of shares outstanding.

Largest holders

  • BlackRock10.00%
  • Dodge & Cox7.55%
  • PRIMECAP Management Company7.33%
  • Vanguard Capital Management, LLC4.50%
  • Vanguard Portfolio Management, LLC4.32%
  • State Street Global Advisors4.31%
  • Norges Bank Investment Management4.24%
  • Viking Global Investors LP3.93%

By investor type

  • Mutual Fund73.19%
  • Hedge Fund18.75%
  • Sovereign Wealth Fund4.24%
  • Public Company2.38%
  • VC/PE Fund1.90%
  • Government Pension Fund1.87%
  • Private Company0.82%
  • Insurance Company0.80%

Reported short interest has risen from 5.27% to 7.30% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q3 +2,091,372 3.5%
State Street Global Advisors Mutual Fund 2026/Q3 +538,823 4.3%
UBS Asset Management Mutual Fund 2026/Q3 +520,743 1.3%
Strategic Advisers LLC Mutual Fund 2026/Q3 +428,794 0.3%
Dimensional Fund Advisors Mutual Fund 2026/Q3 +323,167 2.3%
Renaissance Technologies Corp. Hedge Fund 2026/Q3 +275,900 0.4%
Morgan Stanley Public Company 2026/Q3 +257,323 0.9%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +257,323 0.9%
Vestal Point Capital, LP Hedge Fund 2026/Q3 +2,450,000 3.1%
Deep Track Capital, LP VC/PE Fund 2026/Q3 +2,157,481 1.7%
FMR Mutual Fund 2026/Q3 +1,147,648 2.4%
ARGA Investment Management, LLC Mutual Fund 2026/Q3 +1,039,409 0.5%
The Goldman Sachs Group, Inc. Public Company 2026/Q3 +831,878 0.5%
Defilade Capital Management, L.P. Hedge Fund 2026/Q3 +682,005 0.4%
Norges Bank Investment Management Sovereign Wealth Fund 2026/Q3 +676,874 4.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
29 Sep 2026 Gregory Friberg Executive VP and Chief Research & Development Officer Sale to Issuer -4,086 $60.00 47,732
9 Sep 2026 Robert Plenge Independent Director Other Acquisition +6,140 – 6,140
1 Sep 2026 George Davis Executive Vice President Open Market Disposition -17,557 $66.28 61,003
1 Jun 2026 Mark Enyedy Independent Director Other Acquisition +7,490 – 7,490
1 Jun 2026 Ian T. Clark Independent Chairperson Other Acquisition +7,490 – 14,490
1 Jun 2026 Willard Dere Independent Director Other Acquisition +7,490 – 14,140
1 Jun 2026 Timothy Walbert Independent Director Other Acquisition +7,490 – 7,490
1 Jun 2026 Maykin Ho Independent Director Other Acquisition +7,490 – 7,490
1 Jun 2026 Robert Hombach Independent Director Other Acquisition +7,490 – 14,140
1 Jun 2026 Athena Countouriotis Independent Director Other Acquisition +7,490 – 7,490
1 Jun 2026 Elizabeth Anderson Independent Director Other Acquisition +7,490 – 7,490
1 Jun 2026 Barbara Bodem Independent Director Other Acquisition +7,490 – 7,490
19 May 2026 Cristin Hubbard Executive Vice President Sale to Issuer -2,318 $50.20 7,384
6 May 2026 Gregory Friberg Executive VP and Chief Research & Development Officer Open Market Disposition -3,281 $53.85 51,818
17 Mar 2026 George Davis Executive Vice President Sale to Issuer -1,273 $56.05 78,560
16 Mar 2026 Alexander Hardy Chief Executive Officer Sale to Issuer -4,252 $56.05 214,635
16 Mar 2026 Brian Mueller CFO & Executive VP of Finance Sale to Issuer -2,117 $56.05 123,314
16 Mar 2026 Gregory Friberg Executive VP and Chief Research & Development Officer Sale to Issuer -1,629 $56.05 55,099
16 Mar 2026 Cristin Hubbard Executive Vice President Sale to Issuer -1,245 $56.05 7,580
16 Mar 2026 C. Guyer Executive Vice President Sale to Issuer -1,693 $56.05 74,158

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 14,122,815 7.3% 5.8
15 Oct 2026 12,050,657 6.2% 4.9
30 Sep 2026 11,522,835 6.0% 5.5
15 Sep 2026 10,075,655 5.2% 5.5
31 Aug 2026 9,877,553 5.1% 5.8
14 Aug 2026 10,202,950 5.3% 3.7

Discussion

No comments yet — be the first to weigh in on BMRN.

Sign in to join the discussion.

Scroll to Top